Bruker (NASDAQ:BRKR) Issues FY 2025 Earnings Guidance

Bruker (NASDAQ:BRKR - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.670-2.720 for the period, compared to the consensus earnings per share estimate of 2.680. The company issued revenue guidance of $3.5 billion-$3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

Analysts Set New Price Targets

BRKR has been the subject of several recent research reports. Barclays lowered their price objective on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. The Goldman Sachs Group raised shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price on the stock in a research note on Thursday, December 5th. Bank of America increased their price target on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Guggenheim restated a "buy" rating on shares of Bruker in a research report on Friday, January 17th. Finally, UBS Group began coverage on shares of Bruker in a report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price for the company. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and an average price target of $70.50.

Bruker Stock Down 2.2 %

BRKR traded down $1.11 on Monday, hitting $50.04. The company had a trading volume of 2,044,498 shares, compared to its average volume of 1,412,424. Bruker has a 52-week low of $48.07 and a 52-week high of $94.86. The stock has a fifty day simple moving average of $57.56 and a 200-day simple moving average of $60.48. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The firm has a market capitalization of $7.59 billion, a P/E ratio of 24.06, a P/E/G ratio of 3.81 and a beta of 1.16.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.52% and a net margin of 9.41%. As a group, equities analysts expect that Bruker will post 2.4 EPS for the current fiscal year.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.